Parkinson's disease is a progressive disorder that often deteriorates movement. Researchers at Rhode Island Hospital and The Warren Alpert Medical School of Brown University believe that the gene GIGYF2 may hold the key to developing new treatments for the disease.
In a study report, published online in the American Journal of Human Genetics, the researchers say that mutations in this gene seem to be directly linked with the development of Parkinson's in people who have a family history of the disease.
The researchers believe that studying this gene may provide new treatments for the more common and sporadic forms of the disease.
"These findings may ultimately help open the door to the development of new therapeutic – and possibly even preventive – strategies that target the underlying cause of Parkinson’s disease, improving the quality of life of the many people worldwide who are affected by this devastating disorder," said senior author Dr. Robert J. Smith, director of the division of endocrinology and the Hallett Center for Diabetes and Endocrinology at Rhode Island Hospital and professor of medicine at Alpert Medical School.
The new research also seems to suggest a possible association between Parkinson’s and insulin and the related hormone known as insulin-like growth factor (IGF).
Dr. Smith revealed that GIGYF2 was initially identified nearly five years ago because of its potential involvement in IGF and insulin signaling systems, but its association with Parkinson's was not explored then.